Abstract: An image-based livestock inventory management device includes a data transmission and reception module, a memory storing an image-based livestock inventory management program, and a processor configured to execute the image-based livestock inventory management program stored in the memory, wherein the image-based livestock inventory management program detects each livestock individual by inputting, to a livestock individual detection model, an image collected by at least one camera that captures a doorway of each livestock room which is set as one region of interest (ROI), tracks a movement state of each livestock individual by accumulating and storing center coordinates of detected each livestock individual, generates entry and exit state information of each livestock room by counting an entry action and an exit action of each livestock individual at the doorway of each livestock room for the ROI, and provides inventory information.

Abstract: The present invention relates to a compound selected from the group consisting of cynarine, eravacycline and prexasertib or a pharmaceutically acceptable salt thereof, preferably eravacycline or a pharmaceutically acceptable salt thereof, and to combination of said compounds with other active ingredients, for use in the treatment and/or prevention of viral infections by coronavirus selected from the group consisting of MERS-CoV, SARS-CoV and SARS-CoV-2 virus, to the use of said compound or its combinations in the manufacture of a medicament for the treatment or prevention of said diseases and to a method of treating and/or preventing by administration of said compound or its combinations.

Abstract: The present invention relates to a receptor-binding domain of an IgE-dependent histamine releasing factor (HRF), and a use thereof, and more specifically, ascertains, as an HRF structural region, and a FL domain and an H2 domain which bind to a receptor of HRF existing in a cell membrane, ascertains the C-terminus domain of the HRF, and ascertains that a material binding thereto inhibits IL-8 secretion, thereby determining that the FL and H2 domains and the C-terminus domain can be utilized in: the development of a therapeutic agent for treatment and prevention of HRF-related disease including allergic diseases such as asthma, bronchitis, chronic obstructive pulmonary disease, bronchiectasis, rhinitis, atopic dermatitis, hives (urticaria), hay fever, conjunctivitis, and anaphylaxis; inflammatory diseases such as bronchitis, pneumonia, arthritis, nephritis, psoriasis, dermatitis, Crohn's disease, enteritis, gingivitis, arteriosclerosis, coronary arteritis, hepatitis, Behcet's disease, bladder cancer, prostatit

Abstract: The present invention relates to a receptor-binding domain of an IgE-dependent histamine releasing factor (HRF), and a use thereof, and more specifically, ascertains, as an HRF structual region, and a FL domain and an H2 domain which bind to a receptor of HRF existing in a cell membrane, ascertains the C-terminus domain of the HRF, and ascertains that a material binding thereto inhibits IL-8 secretion, thereby determining that the FL and H2 domains and the C-terminus domain can be utilized in: the development of a therapeutic agent for treatment and prevention of HRF-related disease including allergic diseases such as asthma, bronchitis, chronic obstructive pulmonary disease, bronchiectasis, rhinitis, atopic dermatitis, hives (urticaria), hay fever, conjunctivitis, and anaphylaxis; inflammatory diseases such as bronchitis, pneumonia, arthritis, nephritis, psoriasis, dermatitis, Crohn's disease, enteritis, gingivitis, arteriosclerosis, coronary arteritis, hepatitis, Behcet's disease, bladder cancer, prostatiti

Abstract: The present invention relates to a composition for thermostabilization in the preparation of a human serum albumin formulation, comprising a fatty acid selected from the group consisting of C16 to C22 fatty acids or a pharmaceutically acceptable salt thereof; a method of preparing thermally stabilized human serum albumin, comprising: 1) adjusting a concentration of human serum albumin to 1 to 40 mg/mL; and 2) adding the fatty acid or pharmaceutically acceptable salt thereof to the human serum albumin; and a method of preparing a human serum albumin formulation, comprising adding the fatty acid or pharmaceutically acceptable salt thereof to human serum albumin and thermally treating the resultant.